Faeth Therapeutics, Inc. (FTH)
NASDAQ (CM) NASDAQ (CM) Primary Summary
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know
The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Faeth Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 1.29M | $32.16M | $26.9M | -$5.26M | -16.36% |
 Li Peng China Universal Asset Management Co. Ltd. | 3,600 | $86,400 | $66,763.8 | -$19,636.2 | -22.73% |
 George Song Superstring Capital Management LP | 14,175 | $354,375 | $266,258.95 | -$88,116.05 | -24.87% |
 Drew Phillips Fortitude Family Office LLC | 17 | $506 | $350.2 | -$155.8 | -30.79% |
 Olga Maltseva Catalio Capital Management LP | 14,718 | $126,280 | $275,594.55 | $149,314.55 | 118.24% |
Faeth Therapeutics, Inc. (FTH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Faeth Therapeutics, Inc. ever had a stock split?
Faeth Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Anand Parikh CEO | NASDAQ (CM) Exchange | 81728A207 CUSIP |
| US Country | 29 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Faeth Therapeutics, Inc. is a pioneering clinical-stage biotechnology firm dedicated to enhancing the quality of life and outcomes for individuals battling cancer. The company is focused on exploring innovative approaches through the multi-node inhibition of essential oncogenic pathways, which are critical to cancer progression and survival. By targeting these pivotal pathways, Faeth Therapeutics aims to offer transformative solutions in oncology, bolstering the fight against various forms of cancer.
The flagship program of Faeth Therapeutics, PIKTOR, represents a major advancement in cancer treatment. This investigational therapy is characterized as an all-oral combination therapy designed specifically to target the PI3K/AKT/mTOR signaling pathway, which plays a significant role in cancer cell proliferation and survival. Through this targeted approach, Faeth Therapeutics aspires to improve therapeutic efficacy and patient outcomes in cancer treatment.
Products and Services
- PIKTOR: PIKTOR is the leading investigational combination therapy developed by Faeth Therapeutics. This all-oral treatment is designed to inhibit the PI3K/AKT/mTOR pathway, a critical signaling cascade involved in many cancers. By targeting multiple nodes of this pathway, PIKTOR aims to simultaneously disrupt various cancer-promoting signals, thus enhancing the overall effectiveness of the therapy against cancer cells.
Contact Information
